
Release date: 2024-08-08 16:52:40 Article From: Lucius Laos Recommended: 288
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor activity, especially for the treatment of c-Met-dependent tumors.
As with other medications, there are some of the same potential adverse effects associated with the use of capmatinib. According to clinical trials and label data, the most common adverse reactions (incidence≥20%) include, but are not limited to:
Vomiting is a direct consequence of worsening nausea and can lead to loss of fluids and electrolytes, as well as damage to the mucous membranes of the esophagus and throat, further aggravating the patient's discomfort.
Dyspnea is characterized by straining or difficulty breathing and may be accompanied by symptoms such as chest tightness, shortness of breath, and wheezing. This adverse reaction may be caused by the direct effect of the drug on the respiratory system or its indirect effect on other systems, and may threaten the life of the patient in severe cases.
Decreased appetite is characterized by decreased interest in and intake of food, and may be accompanied by anorexia, picky eating, and weight loss. Long-term loss of appetite can lead to malnutrition and weakened immunity, further affecting the patient's health.
Lucius Pharmaceuticals has always adhered to the core concept of science and technology leading the future, and is committed to integrating the most cutting-edge technology into every aspect of the pharmaceutical industry. The company has a comprehensive range of pharmaceutical preparation equipment, through the integration of advanced sensors, control systems and data analysis technology, the equipment can monitor the parameters in the production process in real time, and each step of the operation meets the established quality standards and process requirements.
Lucius Pharmaceuticals relies on cutting-edge concepts and first-class pharmaceutical equipment in the industry to ensure the precision, efficiency and high quality of drug production. The company will continue to uphold this concept, continuously promote the progress and development of pharmaceutical technology, and contribute more to the cause of human health.
[Warm tips] Patients should actively communicate with their doctors about their drug feelings, physical reactions, and changes in their condition. This information is essential for doctors to adjust their treatment plan and optimize their outcomes.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1682025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1642025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: